GlassScriptPhysician profile
Gary J Birdsall
NPI 1649213596
$13,368.43
in general payments reported to CMS, 2019-2025
54 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $1,473 · 2021: $2,134 · 2022: $2,149 · 2023: $2,180 · 2024: $1,910 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,093 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,093.12 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,624.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,366.24 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,095.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,015.47 | 2019-2025 | |
| Novo Nordisk INC | $1,014.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $896.57 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Astellas Pharma US INC | $735.84 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $674.83 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $591.62 | 2022-2025 | Caplyta |
| Amgen INC. | $337.49 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $332.29 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Vanda Pharmaceuticals INC. | $309.41 | 2024-2025 | Fanapt |
| Allergan, INC. | $308.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $278.43 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $216.02 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Birdsall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.